1. A method for inserting advertising content in broadcast programming, comprising the steps of:
gathering at a viewer device data identifying characteristics of a viewer that is confined to the viewer device;
receiving at the viewer device advertising content;
identifying at the viewer device advertising content corresponding to the confined characteristics of the viewer;
receiving at the viewer device broadcast content;
inserting at the viewer device into the broadcast content the advertising content corresponding to the confined characteristics of the viewer;
displaying at the viewer device the broadcast content with the advertising content matching the confined characteristics of the viewer inserted therein; and
gathering at the viewer device data identifying whether the advertising content matching the confined characteristics of the viewer has been displayed by the viewer device.
2. The method of claim 1, wherein said step of gathering at a viewer device data identifying characteristics of a viewer comprises gathering data regarding at least one of the following: age; address; marital status; income; interests; hobbies; purchasing habits; location; and television viewing habits.
3. A method as in claim 1, wherein the step of gathering at a viewer device data identifying characteristics of a viewer comprises the steps of:
identifying a plurality of categories into which broadcast programming may be grouped; and
recording the frequency and duration with which the viewer is tuned to broadcast programming in each of said plurality of categories.
4. The method of claim 1, wherein the step of identifying at the viewer device advertising content corresponding to the characteristics of the viewer comprises matching data identifying the target audience for advertising content to the characteristics of the viewer.
5. A method as in claim 1, wherein said step of receiving at the viewer device broadcast content comprises receiving broadcast content from one of a direct to home satellite distribution network and a cable television network.
6. A method as in claim 1, wherein said step of receiving at the viewer device advertising content comprises receiving at the viewer device advertising content from a digital subscriber line (DSL) broadband network.
7. A method as in claim 1, further comprising the step of storing at the viewer device advertising content for insertion into broadcast content at a later time.
8. A method as in claim 1, wherein said step of receiving at the viewer device advertising content is performed simultaneously with said step of inserting at the viewer device into the broadcast content advertising content corresponding to the confined characteristics of a viewer.
9. A method as in claim 1, further comprising detecting at the viewer device cue tones in the broadcast content identifying locations where advertising content may be inserted.
10. A computer readable medium having stored thereon computer executable instructions for performing the method as recited in claim 1.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of formula II:
wherein R1-R11 can be the same or different and are selected from: H, halide, substituted or unsubstituted alkyl, heteroalkyl, haloalkyl, heterohaloalkyl, cyclic alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, ester, ether, polyether, alkoxy group, aryloxy group, haloalkoxy group, amino group, alkylcarbonyloxy group, alkoxycarbonyl group, aryloxycarbonyl group, azo group, arylcarbonyloxy group, alkoxycarbonyloxy group, aryloxycarbonyloxy group, sulfinyl group, sulfonyl group, silil group, carbamoyl group, heterocyclic group, nitro group, nitroso group, formyloxy group, isocyano group, cyanate group, isocyanate group, thiocyanate group, isothiocyanate group, N(alkyl)2, N(aryl)2, CH\u2550CH(aryl), CH\u2550CHCH2N(CH3)2, or a functional group of molecular weight of less than about 100,000 daltons; CH\u2550CHCH2N+(CH3)3A, CH\u2550N(alkyl)2A, or N(alkyl)3+A, where A is a charge balancing ion; CN, OH, CHO, COCH3, CO(alkyl), CO2H, CO2Na, CO2K, CH(CH3)OH, CH(CH3)O-alkyl, CH(CH3)O-alkoxy, and CH(CH3)O-aryl;
(CH2)nO-alkoxy, or (CH2)nO-alkyl, where n is an integer from 0 to 8;
C(X)2C(X)3, where X is a halogen;
CO2R12, where R12 is selected from a physiologically acceptable counter ion, a straight or branched chain C1-C20 alkyl, haloalkyl, heteroalkyl, haloheteroalkyl, heterocycle, aryl, heteroaryl, a mono-, di-, or polyhydroxyalkyl residue, a mono-, di-, or polyhydroxyaryl residue, or a functional group of less than about 100,000 daltons;
(CH2)nOH, or (CH2)nOR13, where R13 is selected from alkyl, haloalkyl, heteroalkyl, haloheteroalkyl, heterocycle, aryl, heteroaryl, a protecting group, a mono-, di-, or polyhydroxyalkyl residue, a mono-, di-, or polyhydroxyaryl residue, or a functional group of less than about 100,000 daltons, and n is an integer between 0 and 4;
(CH2)nCO2R14, (CHX)nCO2R14, or (CX2)nCO2R14, where X is a halogen and R14 is selected from H, a physiologically acceptable counter ion, a straight or branched chain C1-C20 alkyl, haloalkyl, heteroalkyl, haloheteroalky;, aryl, heteroaryl, heterocycle, a mono-, di-, or polyhydroxyalkyl residue, a mono-, di-, or polyhydroxyaryl residue, or a functional group of less than about 100,000 daltons, and n is an integer between 1 and 4;
CONH(R15), CONHNH(R15), CO(R15), CON(R15)2, CON(R15)(R16), (CH2)nCONH(R15), (CH2)nCONHNH(R15), (CH2)nCON(R15)2, (CH2)nCOR15, (CH2)nCON(R15)(R16), (CX2)nCONH(R15), (CX2)nCON(R15)2, (CX2)nCON(R15)(R16) (CX2)nCOR15, (CH2)nCONHNH(R15), (CX2)nCONHNH(R15), (CHX)nCONH(R15), (CHX)nCONHNH(R15), (CHX)nCON(R15)2, (CHX)nCON(R15)(R16) where X is a halogen and R15 and R16 can be the same or different and are selected from H, NH2, straight or branched chain C1-C20 alkyl, haloalkyl, haloheteroalkyl, heteroalkyl, aryl, heteroaryl, heterocycle, a mono-, di-, or Polyhydroxyalkyl residue, a mono-, di-, or polyhydroxyaryl residue, an amino acid, an amino acid salt, an amino acid ester, an amino acid amide, a mono-, di-, or polyetheralkyl residue, a mono-, di-, or polyetheraryl residue, or a functional group of less than about 100,000 daltons, and n is an integer between 0 and 4;
S(R17), (CH2)nS(R17), (CH2)nNH(R17), (CH2)nNH(R17), (CH2)nR17, (CH2)nN(R17)(R18), or (CH2)nN(R17)(R18)(R19)+A where R17, R18 and R19 can be the same or different and are selected from H, NH2, straight or branched chain C1-C20 alkyl, haloalkyl, heteroalkyl, haloheteroalkyl, aryl, heteroaryl, heterocycle, amino acids, an amino acid ester, an amino acid amide provided \u2014NH(R17) is part of the amino acid, a mono-, di-, or polyhydroxyalkyl residue, a mono-, di-, or polyhydroxyaryl residue, a mono-, di-, or polyetheralkyl residue, a mono-, di-, or polyetheraryl residue, a functional group of less than about 100,000 daltons, or where R17, R18 and R19 together possess the atoms necessary to constitute an aromatic ring system, n is an integer between 0 and 4, and A is a physiologically acceptable counter ion;
(CH2)nOPO2OR20, (CH2)nPO(OR20)2, (CH2)nPO2R20, or (CH2)nPOR20 where R20 is selected from H, a physiologically acceptable counter ion, a straight or branched chain C1-C20 alkyl, haloalkyl, heteroalkyl, haloheteroalkyl, aryl or heteroaryl, heterocycle, amino acids and salts, esters, or amides thereof, a mono-, di-, or polyhydroxyalkyl residue, a mono-, di-, or polyhydroxyaryl residue, a mono-, di-, or polyetheralkyl residue, a mono-, di-, or polyetheraryl residue, or a functional group of less than about 100,000 daltons, and n is an integer between 0 and 4;
(CH2)nNHCOR21, or (CH2)nNHNHCOR21, where R21 is selected from a straight or branched chain C1-C20 alkyl, haloalkyl, heteroalkyl, haloheteroalkyl, aryl, heteroaryl, heterocycle, amino acids and salts, esters, or amides thereof, or a functional group of less than about 100,000 daltons, and n is an integer between 0 and 4;
SO3R22, SO2NHR22, SO2N(R22)2, SO2NHNHR22 or SO2R22, where R22 is select H, a physiologically acceptable counter ion, a straight or branched chain C1-C20 alkyl, haloalkyl, heteroalkyl, haloheteroalkyl, aryl or heteroaryl, heterocycle, a mono-, di-, or polyhydroxyalkyl residue, a mono-, di-, or polyhydroxyaryl residue, a mono-, di-, or polyetheralkyl residue, a mono-, di-, or polyetheraryl residue, and NHR22 can be an amino acid residue, an amino acid salt, an amino acid ester residue, an amino acid amide residue, or a functional group of less than about 100,000 daltons;
Aryl or substituted aryl, which may bear one or more substituents with a molecular weight of less than or equal to about 100,000 daltons;
R1\u2014R2, R3\u2014R4, R6\u2014R7, R9\u2014R10, R4\u2014R5, R5\u2014R6, R7\u2014R8, R8\u2014R9, R10\u2014R11, or R11\u2014R1, may also possess the atoms necessary to form ring systems, which themselves may possess heteroatoms that may bear one or more functional groups of molecular weight equal to or less than about 100,000 daltons;
with the proviso that at least one of the R1-R11 groups is linked via an organic group that has as part or all of its structure a group Q, which is an amine, an ester, an ether or an amide link, to a complexing agent of general formula IIa, IIb, IIc, IId, IIe:
wherein R24 is selected from a hydrogen, a straight or branched chain C1-C7 alkyl group, a phenyl or benzyl group; L1, L2, L3, L4, independently of one another, are selected from a hydrogen atom or a metal ion equivalent of an element of the atomic numbers 20-32, 37-39, 42-51, or 57-83, which may be radioactive, provided that at least two of L1, L2, L3 and L4 are metal ion equivalents, that other anions are present to compensate for optionally present charges on the porphyrin, and free carboxyhic acid groups that are not required for complexing are optionally present as salts with physiologically compatible inorganic cations, or organic cations, or as esters or amides; and wherein
M is 2H or a diamagnetic or paramagnetic photoactive metal ion selected from Ga3+, Pt2+, Pd2+, Sn4+, In3+, Ge4+, Si4+, Al3+, Zn2+, and Mg2+.
2. A method of using the compound of claim 1 comprising administering the compound to a patient and, after a period of time, imaging targeted tissue of the patient through MRI or radio-diagnostic imaging.
3. A method of using the compound of claim 1 comprising administering the compound to a patient and, after a period of time, irradiating targeted tissue of the patient with an energy source that excites the compound thereby producing a desired therapeutic response in the target tissue.
4. A method of using the compound of claim 1 comprising administering the compound to a patient and, after a period of time, imaging targeted tissue of the patient through MRI or radio-diagnostic imaging then, after a second period of time, irradiating the targeted tissue with an energy source that excites the compound thereby producing a desired therapeutic response in the target tissue.
5. A method for the detection or treatment of tissue comprising administering to a patient a therapeutic amount of the compound of claim 1 locally, systemically, intramuscularly or interperitoneally and irradiating said compound with energy at a wavelength able to excite the molecule, such that a desired therapeutic effect is observed, whereby said tissue belongs to the hematological system, lymphatic reticuloendothelial system, nervous system, endocrine and exocrine system, skeletomuscular system, skin, pulmonary system, gastrointestinal, reproductive system, immune system, cardiovascular system, urinary system, auditory or olfactory system.
6. The method of claim 2, wherein said method is for diagnosing disorders in a vessel wall, tissue adjoining the vessel wall, or material attached to the vessel wall of a coronary, carotid or peripheral vasculature.
7. The method of claim 6 wherein said vessel is an artery or a vein.
8. The method of claim 2 wherein the tissue is atherosclerosis, restenosis or graft disease.
9. The method of claim 3 wherein the tissue is atherosclerosis, restenosis or graft disease.
10. The method of claim 4 wherein the tissue is atherosclerosis, restenosis or graft disease.
11. The method of claim 5 wherein the tissue is atherosclerosis, restenosis or graft disease.
12. The method of claim 4 wherein the therapy is selected from ablation, reduction and stabilization of vessel wall plaque.
13. The method of claim 4 wherein said energy source is selected from light, ultrasound, magnetic force, and electromagnetic radiation in the UVvisible electromagnetic spectrum or near infrared.
14. The method of claim 4 wherein said administration of the compound is prior to, concomitant with, or subsequent to adjunctive interventions, diagnostics or therapies.
15. The method of claim 4 wherein said administration is a single bolus or plurality of doses administered to the patient.
16. A compound of formula IIA:
wherein R1-R6 can be the same or different and are selected from: H, halide, substituted or unsubstituted alkyl, heteroalkyl, haloalkyl, heterohaloalkyl, cyclic alkyl, aryl, substituted aryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, amide, ester, ether, polyether, alkoxy group, aryloxy group, haloalkoxy group, amino group, alkylcarbonyloxy group, alkoxycarbonyl group, aryloxycarbonyl group, azo group, arylcarbonyloxy group, alkoxycarbonyloxy group, aryloxycarbonyloxy group, sulfinyl group, sulfonyl group, silil group, carbamoyl group, heterocyclic group, nitro group, nitroso group, formyloxy group, isocyano group, cyanate group, isocyanate group, thiocyanate group, isothiocyanate group, N(alkyl)2, N(aryl)2, CH\u2550CH(aryl), CH\u2550CHCH2N(CH3)2, or a functional group of molecular weight of less than about 100,000 daltons; CH\u2550CHCH2N+(CH3)3A, CH\u2550N(alkyl)2A, or N(alkyl)3+A, where A is a charge balancing ion; CN, OH, CHO, COCH3, CO(alkyl), CO2H, CO2Na, CO2K, CH(CH3)OH, CH(CH3)O-alkyl, CH(CH3)O-alkoxy, or CH(CH3)O-aryl;
(CH2)nO-alkoxy, or (CH2)nO-aIkyl, where n is an integer from 0 to 8;
C(X)2C(X)3, where X is a halogen;
CO2R7, where R7 is selected from a physiologically acceptable counter ion, a straight or branched chain C1-C20 alkyl, haloalkyl, heteroalkyl, haloheteroalkyl, aryl, heteroaryl, heterocycle, a mono-, di-, or polyhydroxyalkyl residue, a mono-, di-, or polyhydroxyaryl residue, or a functional group of less than about 100,000 daltons;
(CH2)nOH, or (CH2)nOR8, where R8 is selected from alkyl, haloalkyl, heteroalkyl, haloheteroalkyl, aryl, heteroaryl, heterocycle, a protecting group, a mono-, di-, or polyhydroxyalkyl residue, a mono-, di-, or polyhydroxyaryl residue, or a functional group of less than about 100,000 daltons, and n is an integer between 0 and 4;
(CH2)nCO2R9, (CHX)nCO2R9, or (CX2)nCO2R9, where X is a halogen and R9 is selected from H, a physiologically acceptable counter ion, a straight or branched chain C1-C20 alkyl, haloalkyl, heteroalkyl, haloheteroalkyl, heterocycle, aryl, heteroaryl, a mono-, di-, or polyhydroxyalkyl residue, a mono-, di-, or polyhydroxyaryl residue, or a functional group of less than about 100,000 daltons, and n is an integer between 1 and 4;
CONH(R10), CONHNH(R10), CO(R10), CON(R10)2, CON(R10)(R11), (CH2)nCONH(R10), (CH2)nCONHNH(R10), (CH2)nCON(R10)2, (CH2)nCOR10, (CH2)nCON(R10)(R11), (CX2)nCONH(R10), (CX2)nCON(R10)2, (CX2)nCON(R10)(R11), (CX2)nCOR10, (CH2)nCONHNH(R10), (CX2)nCONHNH(R10), (CHX)nCONH(R10), (CHX)nCONHNH(R10), (CHX)nCON(R10)2, or (CHX)nCON(R10)( R11), where X is a halogen and R10 and R11 can be the same or different and are selected from H, NH2, straight or branched chain C1-C20 alkyl, haloalkyl, haloheteroalkyl, heteroalkyl, aryl, heteroaryl, heterocycle, a mono-, di-, or polyhydroxyalkyl residue, a mono-, di-, or polyhydroxyaryl residue, an amino acid, an amino acid salt, an amino acid ester, an amino acid amide, a mono-, di-, or polyetheralkyl residue, a mono-, di-, or polyetheraryl residue, or a functional group of less than about 100,000 daltons, and n is an integer between 0 and 4;
S(R12), (CH2)nS(R12), (CH2)nNH(R12), (CH2)nNHNH(R12), (CH2)nN(R12)2, (CH2)nN(R12)(R13), or (CH2)nN(R12)(R13)(R14)+A, where R12, R13 and R14 can be the same or different and are selected from H, NH2, straight or branched chain C1-C20 alkyl, haloalkyl, heteroalkyl, haloheteroalkyl, aryl, heteroaryl, heterocycle, amino acids, an amino acid ester, or an amino acid amide provided \u2014NH(R13) is part of the amino acid, a mono-, di-, or polyhydroxyalkyl residue, a mono-, di-, or polyhydroxyaryl residue, a mono-, di-, or polyetheralkyl residue, a mono-, di-, or polyetheraryl residue, a functional group of less than about 100,000 daltons, or where R12, R13 and R14 together possess the atoms necessary to constitute an aromatic ring system, n is an integer between 0 and 4, and A is a physiologically acceptable counter ion;
(CH2)nOPO2OR15, (CH2)nPO(OR15)2, (CH2)nPO2R15, or (CH2)nPOR15 where R15 is selected from H, a physiologically acceptable counter ion, a straight or branched chain C1-C20 alkyl, haloalkyl, heteroalkyl, haloheteroalkyl, aryl or heteroaryl, heterocycle, amino acids and salts, esters, or amides thereof, a mono-, di-, or polyhydroxyalkyl residue, a mono-, di-, or polyhydroxyaryl residue, a mono-, di-, or polyetheralkyl residue, a mono-, di-, or polyetheraryl residue, or a functional group of less than about 100,000 daltons, and n is an integer between 0 and 4;
(CH2)nNHCOR16, or (CH2)nNHNHCOR16, where R16 is selected from a straight or branched chain C1-C20 alkyl, haloalkyl, heteroalkyl, haloheteroalkyl, aryl, heteroaryl, heterocycle, amino acids and salts, esters, or amides thereof, or a functional group of less than about 100,000 daltons, and n is an integer between 0 and 4;
SO3R17, SO2NHR17, SO2N(R17)2, SO2NHNHR17 or SO2R17, where R17 is select H, a physiologically acceptable counter ion, a straight or branched chain C1-C20 alkyl, haloalkyl, heteroalkyl, haloheteroalkyl, aryl, heteroaryl, heterocycle, a mono-, di-, or polyhydroxyalkyl residue, a mono-, di-, or polyhydroxyaryl residue, a mono-, di-, or polyetheralkyl residue, a mono-, di-, or polyetheraryl residue, a functional group of less than about 100,000 daltons, and NHR17 can be an amino acid residue, an amino acid salt, an amino acid ester residue, an amino acid amide residue;
Aryl or substituted aryl, which may bear one or more substituents with a molecular weight of less than or equal to about 100,000 daltons; and
R1\u2014R2, and R3\u2014R4 may also possess the atoms necessary to form ring systems, which themselves may possess heteroatoms that may bear one or more functional groups of molecular weight equal to or less than about 100,000 daltons;
with the proviso that at least one of the R1-R4 groups is linked via an organic group that has as part or all of its structure a group Q, which is an amine, an ester, an ether or an amide link, to a complexing agent of general formula IIa, IIb, IIc, IId, IIe:
wherein R24 is selected from a hydrogen, a straight or branched chain C1-C7 alkyl group, a phenyl or benzyl group; L1, L2, L3, L4, independently of one another, are selected from a hydrogen atom or a metal ion equivalent of an element of the atomic numbers 20-32, 37-39, 42-51, or 57-83, which may be radioactive, provided that at least two of L1, L2, L3 and L4 are metal ion equivalents, that other anions are present to compensate for optionally present charges on the porphyrin, and free carboxylic acid groups that are not required for complexing are optionally present as salts with physiologically compatible inorganic cations, or organic cations, or as esters or amides; and wherein
M is 2H or a diamagnetic or paramagnetic photoactive metal ion selected from Ga3+, Pt2+, Pd2+, Sn4+, In3+, Ge4+, Si4+, Al3+, Zn2+, and Mg2+.
17. A method of using the compound of claim 16 comprising administering the compound to a patient and, after a period of time, imaging targeted tissue of the patient through MRI or radio-diagnostic imaging.
18. A method of using the compound of claim 16 comprising administering the compound to a patient and, after a period of time, irradiating targeted tissue of the patient with an energy source that excites the compound thereby producing a desired therapeutic response in the target tissue.
19. A method of using the compound of claim 16 comprising administering the compound to a patient and, after a period of time, imaging targeted tissue of the patient through MRI or radio-diagnostic imaging then, after a second period of time, irradiating the targeted tissue with an energy source that excites the compound thereby producing a desired therapeutic response in the target tissue.
20. A method for the detection or treatment of tissue comprising administering to a patient a therapeutic amount of the compound of claim 16 locally, systemically, intramuscularly or interperitoneally and irradiating said compound with energy at a wavelength able to excite the molecule, such that a desired therapeutic effect is observed, whereby said tissue belongs to the hematological system, lymphatic reticuloendothelial system, nervous system, endocrine and exocrine system, skeletomuscular system, skin, pulmonary system, gastrointestinal, reproductive system, immune system, cardiovascular system, urinary system, auditory or olfactory system.
21. The method of claim 17, wherein said method is for diagnosing disorders in a vessel wall, tissue adjoining the vessel wall, or material attached to the vessel wall of a coronary, carotid or peripheral vasculature.
22. The method of claim 21 wherein said vessel is an artery or a vein.
23. The method of claim 17 wherein the tissue is atherosclerosis, restenosis or graft disease.
24. The method of claim 18 wherein the tissue is atherosclerosis, restenosis or graft disease.
25. The method of claim 19 wherein the tissue is atherosclerosis, restenosis or graft disease.
26. The method of claim 20 wherein the tissue is atherosclerosis, restenosis or graft disease.
27. The method of claim 19 wherein the therapy is selected from ablation, reduction and stabilization of vessel wall plaque.
28. The method of claim 19 wherein said energy source is selected from light, ultrasound, magnetic force, and electromagnetic radiation in the UVvisible electromagnetic spectrum or near infrared.
29. The method of claim 19 wherein said administration of the compound is prior to, concomitant with, or subsequent to adjunctive interventions, diagnostics or therapies.
30. The method of claim 19 wherein said administration is a single bolus or plurality of doses administered to the patient.